LifeStance Health Group (LFST) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for LifeStance Health Group (NASDAQ: LFST):

• 7/21/2026 – LifeStance Health Group had its price target raised by Canaccord Genuity Group Inc. from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 7/14/2026 – LifeStance Health Group had its price target raised by Barclays PLC from $9.00 to $13.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – LifeStance Health Group was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/13/2026 – LifeStance Health Group had its price target raised by KeyCorp from $11.00 to $13.00. They now have an “overweight” rating on the stock.
• 7/4/2026 – LifeStance Health Group was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/13/2026 – LifeStance Health Group was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/5/2026 – LifeStance Health Group is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $9.00 price target on the stock.
• 6/5/2026 – LifeStance Health Group is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $9.00 price target on the stock.
• 5/27/2026 – LifeStance Health Group had its “hold (c-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at LifeStance Health Group

In related news, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. The trade was a 62.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the completion of the transaction, the director directly owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This trade represents a 20.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 7,749,541 shares of company stock valued at $64,017,837. 3.50% of the stock is currently owned by insiders.

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.